Noctrix Health Announces Enrollment of First Patient in The RESTFUL Study and Publication of Positive Pilot Study Results
PLEASANTON, Calif., May 25, 2021 /PRNewswire/ — Noctrix Health, Inc. today announced that the first patient has been enrolled in a multi-center, randomized controlled clinical trial. The RESTFUL Study (ClinicalTrials.gov Identifier: NCT04874155) is a first of its kind two-phase, randomized, double-blind, sham-controlled clinical trial to evaluate the Company’s proprietary wearable NTX100 Neuromodulation System in patients with moderate-severe primary RLS who remain refractory to medications.
“Enrolling our first patient in this multi-center study represents an important milestone in our efforts to advance a potentially game-changing wearable therapeutic for patients who struggle to find symptomatic relief with medications due to side effects or insufficient efficacy,” said Shri Raghunathan, Ph.D., President and CEO of Noctrix Health.
“There are a large number of patients that would benefit tremendously from this potential alternative to dopaminergic treatments, and I am excited to partner with the Noctrix Health team in studying its effectiveness in the medication-refractory RLS population,” said one of the principal investigators, Richard Bogan, MD, Associate Clinical Professor at the University of South Carolina School of Medicine and former CMO of SleepMed, Inc., the largest sleep diagnostic company in the United States.